Poly Medicure targets revenue doubling by FY30

GreyOak summary

Poly Medicure aims to double its revenue by FY30, driven primarily by organic growth in existing orthopaedics and cardiology businesses. The company welcomes the government's extension of the medical device production-linked incentive scheme, which now offers eight years of support. While expanding in developed markets, the firm faces competition from Chinese manufacturers in its renal segment.